Sign in
Active, not recruitingPhase 2

TNF-α Treatment of Blast-Induced Tinnitus

Key facts

Who runs it
Wayne State University
Where
Celebration, Coral Gables, Detroit, and Farmington Hills, United StatesSee the 4 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
88 people, planned
Started
1 Jul 2022
Expected to end
Feb 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Etanercept
  • Saline
Record updated
20 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Tinnitus of at least a moderate severity as defined by a score of ≥ 25 points or higher on the Tinnitus Functional Index (TFI) questionnaire associated with one or more of the following:; Blast- or noise exposure; Traumatic brain injury (TBI) and/or concussion diagnosed by a health care provider
  • Able to provide written informed consent
  • Age: Minimum 18 years of age at the time of enrollment
  • Other concurrent treatments for tinnitus: A four-week washout from any other tinnitus treatment or management program is required prior to entering this study; Hearing aids are permitted if the participant has been wearing them for at least 4 weeks
  • Hearing function: All degrees of hearing function can be included, recognizing that individuals with profound, bilateral hearing loss will not be able to perform tinnitus evaluations and hearing tests but will be able to rate subjective tinnitus loudness, annoyance and impact on life. This is an important sub-population because of the challenges in treating them with acoustic therapy and the need for a medical intervention
  • Additional tinnitus characteristics:; Tinnitus history: Onset associated with blast and/or noise exposure or associated with diagnosed TBI and/or concussion. Subjects will have blast exposure, noise exposure, traumatic brain injury (TBI), and/or concussion impact, defined as exposure/impact less than or longer than six months at time of enrollment; Participants enrolled with tinnitus associated with TBI and/or concussion must have received a diagnosis of TBI and/or concussion by a health care provider; Stability: Constant (not pulsatile or intermittent). c) Location of tinnitus perception: Unrestricted. Tinnitus may be unilateral, bilateral, or perceived in the head

Who cannot take part

  • History or evidence of any of the following: Significant brain malformation; cerebral vascular events (such as strokes); neurodegenerative disorders affecting the brain, such as Parkinson's disease, ALS, or Huntington's disease; multiple sclerosis, Guillain-Barré syndrome, or any other disease involving demyelination disorder or any finding suggesting a demyelination disease or disorder; prior brain surgery; The following surgical procedures are not exclusionary: Evacuation of subdural hematoma, insertion of intracranial pressure monitor device, craniectomy
  • Scheduled to receive a live vaccine during study participation or received a live vaccine within 2 weeks prior to screening visit/procedures
  • Ongoing treatment with or plans to begin taking any of the following contraindicated medications: Cyclophosphamide or sulfasalazine; abatacept, anakinra, or any other immunomodulatory biologic therapy; sulfonylureas, meglitinides, or insulin
  • Subjects who have participated in a drug clinical trial within the last 30 days before the start of this one
  • Active malignant neoplasm such as lymphoma or solid tumors or history of malignant neoplasm, excluding successfully treated squamous cell carcinoma or basal carcinoma of the skin or cervical cancer
  • Diagnosis of congestive heart failure
  • History of diagnosed seizure disorder or epilepsy
  • Subjects who currently have an active infection, including tuberculosis, HIV, hepatitis B, and/or chicken pox; Patients with latent hepatitis B infection are also excluded from participation
  • Diagnosis of an auto-immune disease that, in the opinion of the investigator, would cause a weakened immune system; Autoimmune thyroid disease is not considered an exclusionary autoimmune disease for participation in this study
  • Diabetes
  • Diagnosis of myelodysplastic syndrome or aplastic anemia, white blood cell count < 4000, or platelet count < 150,000
  • Clinically significant out of range laboratory values for protocol required laboratory tests as assessed by the investigator
  • Women who are lactating or are of child-bearing-age without use of contraception
  • Subjects who cannot communicate reliably with research team members or who are not likely to be able to complete the requirements of the trial per the discretion of the investigator
  • Pregnancy or planned pregnancy during the study
  • MMSE score < 24

Where in United States

  • Advent HealthCelebration, United States
  • University of MiamiCoral Gables, United States
  • Wayne State UniversityDetroit, United States
  • Michigan Ear InstituteFarmington Hills, United States

About the trial

What the trial wants to find out

The purpose of this multi-site research study is to determine if Etanercept, compared to a placebo, significantly reduces the severity of tinnitus (ringing in the ears) associated with history of blast and/or noise exposure or associated with Traumatic Brain Injury (TBI) and/or concussion. Individuals who qualify will be randomized into one of two groups: The group receiving the medication Etanercept or the group receiving a saline solution placebo.

The 2 groups in the trial

  • Etanercept Injection GroupTreatment being tested

    Subjects will receive 2 X 25mg/ 1ml etanercept injection (experimental) weekly for 12 weeks.

    Treatment: Etanercept

  • Placebo Injection GroupPlacebo, for comparison

    Subjects will receive 2 X 1ml saline injection (placebo) weekly for 12 weeks.

    Treatment: Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus
Record updated
20 October 2026